Overview
Biognosys provides next-generation mass spectrometry-based proteomics contract research services to accelerate pharma and biotech drug discovery, development, and clinical trials. Key offerings include unbiased protein expression profiling from tissues and biofluids, drug target identification and validation, biomarker discovery, and custom panels for absolute quantification using proprietary HRM-MS and PQ500 technologies. They have expanded into multiomics with biocrates metabolomics and lipidomics services available in Europe and the US.
Frequently asked questions
- What proteomics technologies does Biognosys offer?
- Biognosys offers HRM-MS for high-content protein quantification, LiP-MS for drug target deconvolution, PQ500 reference peptides for plasma proteomics, and P2-iST for deep plasma proteome analysis identifying nearly 6,000 proteins.
- What services support drug development stages?
- Services cover target discovery and validation, mechanism of action studies, biomarker discovery in tissues and biofluids, and clinical proteomics across all research phases to de-risk drug R&D.
- Where are Biognosys services available?
- Proteomics and expanded multiomics services including metabolomics and lipidomics are offered from laboratories in Europe and the US near Boston.